Alamar Biosciences, Inc. (ALMR)
| Market Cap | 2.38B |
| Revenue (ttm) | 100.42M +195.2% |
| Net Income | -49.66M |
| EPS | -2.10 |
| Shares Out | 69.39M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 339,899 |
| Open | 32.97 |
| Previous Close | 32.46 |
| Day's Range | 32.80 - 34.62 |
| 52-Week Range | 18.85 - 38.54 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 35.40 (+3.03%) |
| Est. Earnings | Nov 23, 2026 |
About ALMR
Alamar Biosciences, Inc., a proteomics company, develops a proteomic liquid biopsy platform and sells instruments, consumables, and services to early detection of diseases. The company develops NULISA technology, a proteomics platform that detects and quantifies protein biomarkers. It offers ARGO high throughput (HT) System, a fully automated precision proteomics platform, performs ultra-high sensitivity and multiplexed analysis to support biomarker analysis across the continuum of discovery, translational research and ultimately, and diagnosti... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for ALMR stock is "Buy." The 12-month stock price target is $35.4, which is an increase of 3.03% from the latest price.
News
Lancet study using Alamar’s technology reveals divergent responses to Alzheimers
The company states: “Alamar Biosciences (ALMR) announced the publication in The Lancet Neurology of the first longitudinal cohort study to evaluate a broad panel of plasma biomarkers in patients recei...
Lancet Neurology Study Using Alamar Biosciences' Technology Reveals Divergent Biological Responses to Alzheimer's Treatment
Blood biomarkers associated with amyloid clearance differ from those associated with cognitive decline in patients receiving lecanemab Blood biomarkers associated with amyloid clearance differ from th...
Alamar Biosciences rises 15.1%
Alamar Biosciences (ALMR) is up 15.1%, or $4.82 to $36.83.
Alamar Biosciences rises 9.4%
Alamar Biosciences (ALMR) is up 9.4%, or $3.01 to $35.02.
Alamar Biosciences Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Proteomics is at an inflection point, with multiplex testing and high sensitivity enabling new diagnostic and research applications. The platform's unique combination of performance pillars, rapid product expansion, and strong financial growth position it to capture significant market share as it pursues FDA clearance and expands into new disease areas.
Alamar Biosciences to Participate in Morgan Stanley 24th Annual Global Healthcare Conference
FREMONT, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today announced t...
Alamar Biosciences price target raised to $31 from $30 at BofA
BofA raised the firm’s price target on Alamar Biosciences (ALMR) to $31 from $30 and keeps a Neutral rating on the shares. A “strong” Q2 report reinforces strong early platform…
Alamar Biosciences price target raised to $32 from $28 at Stifel
Stifel raised the firm’s price target on Alamar Biosciences (ALMR) to $32 from $28 and keeps a Buy rating on the shares after the company posted a Q2 beat and…
Alamar Biosciences price target raised to $35 from $32 at JPMorgan
JPMorgan analyst Casey Woodring raised the firm’s price target on Alamar Biosciences (ALMR) to $35 from $32 and keeps an Overweight rating on the shares.
Alamar Biosciences expands Alzheimer’s Data Initiative deal with 86K samples
Alamar Biosciences (ALMR) announced an expansion of its strategic partnership with the Alzheimer’s Disease Data Initiative and Gates Ventures. The expanded agreement adds profiling of 86,000 plasma sa...
Alamar Biosciences reports Q2 EPS (22c), consensus (32c)
Reports Q2 revenue $29.4M, consensus $25.94M. “We delivered a strong second quarter with consumable revenue growing nearly 150% year-over-year,” said Yuling Luo, CEO of Alamar Biosciences (ALMR). “Wit...
Alamar Biosciences sees FY26 revenue $116M-$120M, consensus $113.22M
16:32 EDT Alamar Biosciences (ALMR) sees FY26 revenue $116M-$120M, consensus $113.22M
Alamar Biosciences Earnings Call Transcript: Q2 2026
Q2 2026 revenue grew 82% year-over-year to $29.4 million, driven by strong consumables demand and platform adoption, with gross margin reaching 60%. Full-year revenue is projected at $116–$120 million, and the company remains well-capitalized post-IPO to support growth and R&D expansion.
Alamar Biosciences Earnings release: Q2 2026
Alamar Biosciences released its Q2 2026 earnings on August 10, 2026, summarizing the period's financial results.
Alamar Biosciences Slides: Q2 2026
Alamar Biosciences has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 10, 2026.
Alamar Biosciences Quarterly report: Q2 2026
Alamar Biosciences has published its Q2 2026 quarterly earnings report on August 10, 2026.
Alamar Biosciences Launches NULISAseq™ Immune 340 Panel for Comprehensive Profiling of the Immune Proteome
Expanded panel advances the understanding of immune system across translational and clinical research in cancer, cardiovascular and metabolic diseases, autoimmune diseases and aging
Alamar Biosciences price target raised to $34 from $30 at TD Cowen
TD Cowen raised the firm’s price target on Alamar Biosciences (ALMR) to $34 from $30 and keeps a Buy rating on the shares. The firm adjusted targets in the tools…
Alamar Biosciences to Report Second Quarter 2026 Financial Results on August 10, 2026
FREMONT, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in Precision Proteomics dedicated to enabling the earliest detection of disease, today announced it...
Alamar teams with research universities to launch proteomics initiatives
Alamar Biosciences (ALMR) announced a partnership with research universities to launch a national-scale proteomics initiative using Alamar Biosciences’ NULISAseq Neuro 220 panel to accelerate biomarke...
Alamar Biosciences Partners with Leading Research Universities to Launch National Initiative Advancing Blood-Based Biomarkers for Neurodegenerative Diseases
National-scale initiative will profile ~21,000 plasma samples from 10,000 Alzheimer's Disease and Related Dementias (ADRD) participants using Alamar Biosciences' NULISAseq™ Neuro 220 panel. | Resultin...
Alamar Biosciences NULISA Data Featured in More Than 140 Scientific Presentations at AAIC 2026, Highlighting Advances in Blood-Based Alzheimer's Biomarker Profiling
Company to host scientific workshop featuring emerging eMTBR-Tau and BD-pTau217 research data for Alzheimer's disease detection and staging Company to host scientific workshop featuring emerging eMTBR...
Alamar Biosciences Launches the First Multiplexed Blood-based Immunoassay for eMTBR-Tau, One of the Most Important Biomarkers in Alzheimer's Disease Research
eMTBR-Tau offers a non-invasive, blood-based measurement of the tau tangle burden, the core pathology associated with disease progression and cognitive decline in Alzheimer's disease | Immunoassay for...
Alamar Biosciences Makes Home-Collected Fingerstick Samples Compatible with Ultra High-Sensitivity, Multiplex Proteomics
NULISA™ DBS Extraction Kit recovers proteins from dried blood spot and dried plasma spot microsamples collected on leading third-party remote sampling devices | Workflow extends NULISA into longitudin...
Alamar Biosciences Transcript: Bank of America Global Healthcare Conference 2026
A precision proteomics platform launched in 2024 has achieved rapid adoption, especially in neurology and Alzheimer's research, with strong revenue growth and industry-leading sales efficiency. Strategic priorities include expanding content, commercial reach, and moving toward clinical diagnostics, with FDA submission expected next year.